$ALKS News

Baird Maintains Outperform on Alkermes, Raises Price Target to $48

Alkermes Gains Momentum After Sleep Disorder Trial Clears Key Hurdles

Alkermes Topline Results From Revitalyz Phase 3 Study Of Lumryz Extended-release Oral Suspension For Idiopathic Hypersomnia Met The Study's Primary Endpoint, Demonstrating Statistically Significant Improvements In Excessive Daytime Sleepiness Compared To Placebo; Plans To File Supplemental Application To FDA By The End Of 2026

Alkermes plc 2026 Q1 - Results - Earnings Call Presentation

UBS Maintains Buy on Alkermes, Raises Price Target to $48

Alkermes Analysts Increase Their Forecasts Following Strong Q1 Results

Wells Fargo Maintains Overweight on Alkermes, Raises Price Target to $44

Alkermes: A Sleep Medicine Platform Hidden Inside A Mature CNS Company

Needham Maintains Buy on Alkermes, Raises Price Target to $50

Alkermes plc (ALKS) Q1 2026 Earnings Call Transcript

Alkermes plc (NASDAQ:ALKS) Reports Mixed Q1 Results, Beats Revenue Forecasts but Posts Wider Than Expected Loss

Alkermes Raises FY2026 GAAP EPS Guidance from $(0.80)-$(0.68) to $(0.52)-$(0.41) vs $(0.54) Est; Affirms FY2026 Sales Guidance of $1.730B-$1.840B vs $1.798B Est

Alkermes Q1 EPS $(0.40) Beats $(0.52) Estimate, Sales $392.911M Beat $359.848M Estimate

Alkermes Plc (NASDAQ:ALKS) Shows Strong Technical Setup with High Breakout Potential

Alkermes Says 56-Week Post Hoc Analysis Of Lybalvi (Olanzapine And Samidorphan) In Adult Schizophrenia Patients In The Journal Of Clinical Psychiatry Shows Sustained Reduction in Hard-To-Treat Negative Symptoms

Preparation is key to understanding global trade compliance for trials

B of A Securities Maintains Neutral on Alkermes, Raises Price Target to $36

Alkermes Announces Initiation of Phase 3 Brilliance Studies Evaluating Alixorexton for the Treatment of Narcolepsy Type 1 and Type 2

Alkermes Initiates Brilliance Studies Phase 3 Program Of Alixorexton For Adults With Narcolepsy Type 1 and Type 2

Piper Sandler Maintains Overweight on Alkermes, Lowers Price Target to $43